Key Takeaways AMZN posted Q4 net sales of $213.4B, beating estimates, while EPS rose 5% year over year but missed.AWS revenues grew 24% to $35.6B, the fastest pace in 13 quarters, driven by core demand and AI services.AMZN plans about $200B in 2026 capex, largely for AWS, pressuring free cash flow and rattling shares.Amazon.com (AMZN) shares dipped in after-hours trading on Thursday after the company delivered fourth-quarter 2025 earnings of $1.95 per share, which increased 5% from the year-ago quarter but ...

Here’s how to give your holiday card an ’80s makeover right in Search: 1️⃣ Open the Google app. 2️⃣ Tap Lens. 3️⃣ Hit the 🍌, and use the prompt: “put me in an 80s christmas scene.” #GoogleGemini #GoogleSearch #NanoBanana ...

[confidently] Oookay I got this. ...

Core Insights - Tempus AI (TEM) is advancing its suite of algorithms and diagnostic software across multiple medical fields, including oncology, digital pathology, radiology, cardiology, and neuropsychology [1][9] Company Developments - Tempus has partnered with Northwestern University's Abrams Center to utilize AI for rapid advancements in Alzheimer's disease research, employing its AI-powered data analytics platform, Lens, to analyze genomic data [2] - The company has received two new FDA 510(k) clearances for its updated Tempus Pixel cardiac imaging platform and ECG–Low EF software, enhancing capabilities in cardiac MR image analysis and identifying patients with reduced left ventricular ejection fraction [3][9] - Strategic acquisitions have bolstered Tempus' position in the market, including the acquisition of Arterys in 2022 for AI tools in imaging data analysis and Paige, which brought a dataset of nearly 7 million clinically annotated pathology slides [4][9] Industry Context - GE HealthCare has launched the Voluson Performance series for women's health ultrasound and is acquiring icometrix for AI-powered brain imaging analysis [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' stock has increased by 74% over the past year, significantly outperforming the industry, which saw a decline of 1.5%, while the S&P 500 composite rose by 14.5% [7] Valuation Metrics - Tempus currently has a forward 12-month Price-to-Sales (P/S) ratio of 8.76X, compared to the industry average of 5.77X, indicating a higher valuation [10] Earnings Estimates - The loss per share estimate for Tempus AI for 2025 has remained unchanged over the past 30 days, with estimates at -0.05 for the current quarter, -0.13 for the next quarter, and -0.65 for the current year [11][12]

Remembered that zksync paid 0.5% of $ZK supply to launch Lens on zkSynchttps://t.co/5SH9GWI6i0Ignas | DeFi (@DefiIgnas):zkSync reportedly paid 0.5% of the total $ZK supply to bring Lens to zkSync.That's $22.5m at the current price of $0.21.Sounds like a lot, but with so many technically similar L2s, competition is fierce. Only L2s with the best dApps will prevail. ...

Core Insights - Alphabet is well positioned to benefit from the growth of artificial intelligence (AI) over the next decade, extending its strengths beyond online search and ads [1] Cloud Computing Leadership - Alphabet is currently the No. 3 cloud computing infrastructure company by market share but is considered best positioned for future growth due to its complete tech stack [2] - The Gemini foundational large language model (LLM) is consistently ranked among the best, allowing Alphabet to integrate it throughout its cloud stack without relying on third-party models [3] Custom AI Chips Development - Alphabet has been developing tensor processing units (TPUs) for over a decade, now in their seventh generation, and has deployed AI ASICs at a scale unmatched by competitors [4] - TPUs offer performance, efficiency, and cost advantages for specific AI workloads, particularly designed for the TensorFlow framework [5] Search and AI Integration - Alphabet remains the leader in internet search, leveraging its distribution advantages through its widely used browser and smartphone operating system [7] - AI features have been integrated into its search platform, enhancing user experience and driving more search queries [8] Advertising Network Strength - Alphabet has built one of the most expansive ad networks globally, effectively meeting the needs of both large clients and smaller local merchants [9] Symbiosis of Cloud and Search - The integration of cloud computing and search/AI businesses provides Alphabet with a structural cost advantage over competitors that rely on high-cost GPUs [10] Future Outlook - Overall, Alphabet is positioned as one of the best companies to capitalize on the next decade of AI growth [11]

Summary of Tempus AI Conference Call Company Overview - **Company**: Tempus AI - **Industry**: Life Sciences and Diagnostics Key Points AI Integration in Diagnostics and Biopharma - Tempus AI leverages AI across its operations, focusing on enhancing patient care through data and technology [4][5][6] - The company has developed platforms like Hub and Lens to facilitate interaction with diagnostic tests and build patient cohorts, respectively [4][5] - A partnership with AstraZeneca and Pathos aims to create a foundation model to extract insights from large datasets [6] Financial Performance - The third quarter reported a **28% organic growth**, with specific segments showing: - **Genomics**: High 20s growth - **Ambry**: 33% growth - **Data Licensing**: 37% growth [10][12] - Adjusted EBITDA turned positive, marking a significant milestone for the company [13] Oncology and Hereditary Testing - Oncology volumes grew by **27%**, while Ambry benefited from market disruptions in hereditary screening [12][42] - The hereditary testing market is expected to moderate as share gains stabilize [12] Data Licensing and Contracts - Total remaining contract value exceeded **$1 billion**, with a net revenue retention rate of **140%** [48] - New contracts included a **$66 million deal** with a biotech customer and expansions with existing clients [48] - The company anticipates strong engagement from both big pharma and biotech sectors [48] Market Position and Competition - Tempus AI has established connections with over **5,000 institutions**, enhancing its data collection and diagnostic capabilities [19] - The company emphasizes ease of use and connectivity as key differentiators against competitors [20] Reimbursement Trends - Average Selling Prices (ASPs) have increased to approximately **$1,600**, with expectations for **40%** of xT volumes to transition to ADLT pricing by year-end [22][23] - The company aims for **85%** of xT volumes to shift to ADLT pricing by the end of 2026 [23] Clinical Trials and CRO Business - The CRO segment has faced headwinds, but the acquisition of a small CRO aims to enhance clinical trial matching capabilities [61] - The company does not prioritize aggressive growth in the CRO sector but sees potential stabilization as funding for CROs improves [61] Investment and Growth Strategy - Tempus AI plans to reinvest about **two-thirds** of incremental gross profit back into the business over the next three years to support growth [64] - The company aims for long-term growth rates of **25-30%**, focusing on sustainable growth rather than maximizing quarterly revenue [58][64] Gross Margins and Future Outlook - Genomics business margins are expected to stabilize around **low 60%**, while data operations may achieve **mid 70%** margins [66] - AI applications, though currently a small revenue source, are anticipated to positively impact margins as they scale [68] Upcoming Developments - Data from a new ultra-high sensitivity assay for MRD is expected in **2026**, with further developments in breast cancer and immuno-oncology to follow in **2027** [38][39] Additional Insights - The company is cautious about the competitive landscape in MRD testing, focusing on leveraging existing data connections and insights to gain market share [34][35] - Tempus AI's strategy emphasizes long-term relationships with clients to ensure sustained growth and value delivery [58][59]

Did you see people are giving their selfies the gallery treatment, but weren’t sure how to lean in. Here’s how to do it using Nano Banana directly in Google Search. Open Lens in your Google App.Tap the banana, and go bananas. What a masterpiece. Go ahead, make your selfies museum-worthy today. ...

Core Insights - Tempus AI Inc. (TEM) is actively pursuing collaborations to enhance its financial strategy and drive inorganic growth, including a partnership with Whitehawk Therapeutics focused on antibody-drug conjugate (ADC) cancer treatments [1][8] - The global ADC market is experiencing significant growth, with a projected CAGR of 15.2% from 2025 to 2028, increasing from $7.6 million in 2022 to $9.7 million in 2023 [2] - Tempus is leveraging its AI platform to provide actionable insights for biotech partners, facilitating smarter decision-making in drug development [2][8] Collaborations and Partnerships - Tempus has entered a multi-year collaboration with The Abrams Research Center at Northwestern University to utilize AI for Alzheimer's disease research, focusing on genomic data analysis [3] - A partnership with Verastem Oncology aims to develop a companion diagnostic test for KRAS-mutant recurrent low-grade serous ovarian cancer, utilizing Tempus' FDA-approved xT CDx assay in clinical trials [4][8] - Guardant Health and Quest Diagnostics have announced a collaboration to offer Guardant's FDA-approved Shield blood test for colorectal cancer screening, highlighting the trend of strategic partnerships in the oncology field [5][6] Market Performance - Over the past year, Tempus AI shares have increased by 90.2%, significantly outperforming the industry growth of 27.4% and the S&P 500's 16.6% improvement [7] - Despite strong stock performance, TEM is currently trading at a forward Price-to-Sales (P/S) ratio of 10.52X, which is higher than the industry average of 5.90X, indicating a potentially expensive valuation [9] Financial Estimates - The loss per share estimate for Tempus AI for 2025 has remained unchanged over the past 30 days, with current estimates at -$0.16 for the current quarter and -$0.69 for the current year [10][11]

Music Industry Trends - The document suggests a focus on musical elements, specifically a "funky techno beat" [1] - The repetition of "Ba-na-na" and "Buh-buh-buh-nan-nuh" indicates a potential emphasis on catchy, repetitive hooks in music production [1] Song Structure Analysis - The lyrics consist of simple, repetitive syllables, potentially targeting a broad audience or aiming for easy memorability [1]